CAS 258871-59-9

PF-1163A

CAS: 258871-59-9

PF-1163A, a depsipeptide antifungal compound isolated from Penicillium, blocks ergosterol synthesis with an IC50 of 12 ng/ml. This compound specifically inhibits the enzyme ERG25p, a C-4 methyl oxidase in the ergosterol biosynthetic pathway, leading to its antifungal activity. Notably, in Saccharomyces cerevisiae modified to express ERG biosynthesis genes, PF-1163A exhibits an inhibition concentration (MIC value) of 12.5 µg/ml against ERG25p, though strains overexpressing ERG25p show resistance. Additionally, PF-1163A effectively suppresses the growth of Candida albicans (MIC = 8 µg/ml), without affecting other Candida species, Aspergillus fumigatus, or HepG2 cells. Remarkably, it enhances the efficacy of fluconazole against azole-resistant C. albicans strains, showing a significant decrease in MICs (1 and 0.0078 µg/ml alone and in combination, respectively). PF-1163A distinguishes itself from PF-1163B by its more polar nature.

Formula: C₂₇H₄₃NO₆

Color and Shape: Solid

Molecular weight: 477.6

Ref: TM-TN7560

PF 1163A

CAS: 258871-59-9

PF 1163A is a medicinal compound that has shown promising results in the treatment of cancer. It is an analog of a protein found in human urine and has been shown to inhibit kinases, which are enzymes involved in cell signaling pathways that can contribute to cancer growth. PF 1163A has been tested on Chinese hamster ovary cells and has been shown to induce apoptosis, or programmed cell death, in cancer cells. As an anticancer agent, PF 1163A acts as a kinase inhibitor and may have potential as a tumor suppressor. Further research is needed to fully understand the mechanism of action of this compound and its potential as a cancer therapy.

Formula: C₂₇H₄₃NO₆

Purity: Min. 95%

Molecular weight: 477.6 g/mol

Ref: 3D-IKA87159